Navigation Links
R-Tech Ueno Notifies R&D Items
Date:7/30/2009

TOKYO, July 31 /PRNewswire/ -- R-Tech Ueno, Ltd. announced on July 29 after discussing its R&D policy at a meeting of the board of directors held on the day and determined the R&D items as follows.

The company intends to actively strengthen R&D in the ophthalmologic & dermatological fields that are its priority and exclusive areas, and promote relevant affiliation, etc. with external entities.

1. Development code UF-021 (eye diseases)

The item in question is isopropyl unoproston, the effective ingredient of "Rescula(R) eyedrop 0.12%" that is marketed as a therapeutic drug for glaucoma and ocular hypertension. This drug is now being developed by R-Tech Ueno for the indication of retinitis pigmentosa. The drug is introduced to Sucampo Pharma Americas Ltd. in the USA to be developed for the indication of atrophic age-related macular degeneration.

2. Development code RTU-007 (eye diseases)

The license is obtained from Astellas Pharma Inc. for the substance to inhibit the enzyme that increases in patients with diabetes mellitus. We intend to proceed with the development of this substance to be indicated for diabetic cataract, diabetic retinopathy and age-related macular degeneration.

3. Development code RU-10 (eye diseases)

Dry eye is targeted for development of the drug that contains gene recombination human serum albumin as an effective ingredient. Though the clinical study is currently interrupted, we intend to look for overseas affiliation soon because the need for treatment of dry eye is globally unmet (that is, there are currently few therapeutic drugs).

4. Development code RK-023 (dermatological diseases)

This item is a physiologically active fatty acid derivative that is a new compound developed by R-Tech Ueno and is being developed as a drug indicated for male pattern alopecia. We intend to proceed with negotiations for affiliation in Japan and abroad in the future. We also plan to newly develop this drug indicated for eyelash hypotrichosis.

5. Development code RTU-1096 (dermatological and neurological diseases)

This compound newly developed by R-Tech Ueno demonstrates an unconventional action, VAP-1* inhibition. We intend to develop this compound as a drug indicated for atopic dermatitis, contact dermatitis and psoriasis vulgaris in the dermatological field, and diabetic neuropathy in the neurological field.

We plan to report on the development status of each item on the home page of R-Tech Ueno.

*VAP-1 inhibitor

Vascular adhesion protein-1 (VAP-1) is also called semicarbazide-sensitive amine oxidase (SSAO). There are two types of VAP-1/SSAO, that is, the membrane-binding type present in the vascular endothelium and the free type present in the serum. The former serves as a molecule adherent to white blood cells and lymphocytes and is involved in inflammation while the latter detoxifies amine in the living body by its amine oxidase activity. In other words, VAP-1 is a protein that demonstrates two different functions. The increase in VAP-1/SSAO activity is observed in the serum and various tissues of patients with diabetes mellitus, atopic dermatitis, obesity, arteriosclerosis, heart disease, etc. In this regard, VAP-1 inhibitor inhibits the excessive function of VAP-1/SSAO.

About R-Tech Ueno, Ltd.

    Representative Director & President: Yukihiko Mashima
    Head Office: 1-1-7 Uchisaiwai-cho, Chiyoda-ku, Tokyo
    Code No.4573, Osaka Securities Exchange; Hercules


    CONTACT:  Koji Nakamura
              Business Management Department
              R-Tech Ueno, Ltd.
              Tel: +81-3-3596-8011
              e-mail: koji.nakamura@rtueno.co.jp


'/>"/>
SOURCE R-Tech Ueno, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Extraordinary General Meetings Statement - XTL Notifies NASDAQ of Compliance with Marketplace Rule 4350(d)(2)
2. AMEX Notifies Signalife That It Has Accepted Signalifes Plan of Compliance
3. AMEX Notifies Signalife that It Will Need to Comply with Minimum Stockholders Equity Requirement
4. Boston Scientific Announces First Quarter Special Items
5. Arpida Announces Agenda Items for Shareholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 22, 2017 , ... Researchers face a fundamental ... samples to full-size tissues, bones, even whole organs to implant in people to ... blood deep into the developing tissue. , Current bioengineering techniques, including 3-D ...
(Date:3/22/2017)... JERUSALEM , March 22, 2017 ... ( www.oramed.com ), ... of oral drug delivery systems, announced today that ... Officer, will deliver a presentation titled, "Oral Insulin ... upcoming Cambridge Healthtech Institute,s Oligonucleotide and Peptide Therapeutics ...
(Date:3/22/2017)... 22, 2017 /PRNewswire/ - FACIT announced a seed ... "Propellon"), a start-up created by FACIT focused on ... investment, combined with non-dilutive capital, achieves a targeted ... funding enables Propellon to accelerate the nomination of ... financing and/or entering a strategic partnership for clinical ...
(Date:3/22/2017)... ... March 21, 2017 , ... Okyanos Cell Therapy has ... part of their live events series, “Stem Cell Therapy: The Next Phase in the ... the 2013 Stem Cell Research and Therapy Act, Okyanos maintains a mission ...
Breaking Biology Technology:
(Date:2/28/2017)... 2017 News solutions for biometrics, bag drop ... ... 14 to 16 March, Materna will present its complete end-to-end ... travel is a real benefit for passengers. To accelerate the ... passenger touch point solutions to take passengers through the complete ...
(Date:2/24/2017)... , Feb. 24, 2017  EyeLock LLC, a leader ... its elite iris biometric solution on the latest ... LTE at Mobile World Congress 2017 (February ... Booth in Hall 3, Stand 3E10. ... Qualcomm Haven™ security platform—a combination of hardware, ...
(Date:2/16/2017)... 16, 2017  Genos, a community for personal ... has received Laboratory Accreditation from the College of ... to laboratories that meet stringent requirements around quality, ... processes. "Genos is committed to maintaining ... We,re honored to be receiving CAP accreditation," said ...
Breaking Biology News(10 mins):